title: SB-480848. GlaxoSmithKline.
abstract: SB-480848 is a reversible lipoprotein-associated phospholipase A2 inhibitor under development by GlaxoSmithKline for the potential treatment of atherosclerosis. Phase II trials with SB-480848 are currently underway.
authors.affiliation: Lexicon Pharmaceuticals, 350 Carter Road, Princeton, NJ 08540, USA. drotella@lexpharma.com
authors.forename: David P
authors.initials: DP
authors.lastname: Rotella
mesh_terms: D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003324:Coronary Artery Disease / Q000188:drug therapy; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D006801:Humans; D010741:Phospholipases A / Q000037:antagonists & inhibitors; D054467:Phospholipases A2; D011744:Pyrimidinones / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D001713:Biphenyl Compounds; D004048:Diethylamines; D013440:Sulfides
chemical_list: D004791:Enzyme Inhibitors; D010741:Phospholipases A; D054467:Phospholipases A2; D011744:Pyrimidinones; C529040:darapladib; D001713:Biphenyl Compounds; D004048:Diethylamines; D013440:Sulfides